Loading company…
Orikine Bio develops engineered cytokine therapies for immune-mediated diseases.
Orikine Bio is a Centre for Genomic Regulation spin-off developing cytokine-based therapies for autoimmune and inflammatory diseases. Its platform is intended to support drug development across immune-mediated conditions, including its ORK-1 project. Founded in 2022 and based in Barcelona, the company received EUR 800,000 million in grant funding in December 2024, led by Ministerio de Ciencia, Innovación y Universidades.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in